Regulatory Perspective on Remaining Challenges for Utilization of Pharmacogenomics-Guided Drug Developments

• Uyama Y , IshiguroA, NakamuraH, ToyoshimaS. Use of biomarkers in drug development: Japanese perspectives. In: Predictive Approaches in Drug Discovery and Development: Biomarkers and In Vitro/In Vivo Correlations. Williams JA, Koup J, Lalonde R, Christ DD (Eds). John Wiley & Sons Inc., NJ, USA, 269–287 (2012).
   Google Scholar
• Frueh FW , AmurS, MummaneniP et al. Pharmacogenomic biomarker information in drug labels approved by the United States food and drug administration: prevalence of related drug use. Pharmacotherapy 28(8) , 992–998 (2008).
   PubMed Web of Science ®Google Scholar
• Poste G , CarboneDP, ParkinsonDR, VerweijJ, HewittSM, JessupJM. Leveling the playing field: bringing development of biomarkers and molecular diagnostics up to the standards for drug development. Clin. Cancer Res.18(6) , 1515–1523 (2012).
   PubMed Web of Science ®Google Scholar
• La Thangue NB , KerrDJ. Predictive biomarkers: a paradigm shift towards personalized cancer medicine. Nat. Rev. Clin. Oncol.8(10) , 587–596 (2011).
   PubMed Web of Science ®Google Scholar
• Wang S -J, O‘Neill RT, Hung HJ. Statistical considerations in evaluating pharmacogenomics-based clinical effect for confirmatory trials. Clin. Trials7(5) , 525–536 (2010).
   PubMed Web of Science ®Google Scholar
• Warner AW , BhathenaA, GilardiS et al. Challenges in obtaining adequate genetic sample sets in clinical trials: the perspective of the industry pharmacogenomics working group. Clin. Pharmacol. Ther. 89(4) , 529–536 (2011).
   PubMed Web of Science ®Google Scholar
• Ricci DS , BroderickED, TcheletA et al. Global requirements for DNA sample collections: results of a survey of 204 ethics committees in 40 countries. Clin. Pharmacol. Ther. 89(4) , 554–561 (2011).
   PubMed Web of Science ®Google Scholar
• Warner A , NelsenA, BhathenaA et al. Enabling pharmacogenomic clinical trials through sampling. Pharmacogenomics 11(12) , 1649–1654 (2010).
   PubMed Web of Science ®Google Scholar
• Goodsaid F . Challenges of biomarkers in drug discovery and development. Expert Opin. Drug Discov.7(6) , 457–461 (2012).
   PubMed Web of Science ®Google Scholar
• Dieterle F , SistareF, GoodsaidF et al. Renal biomarker qualification submission: a dialog between the FDA-EMEA and predictive safety testing consortium. Nat. Biotech. 28(5) , 455–462 (2010).
   PubMed Web of Science ®Google Scholar
• Thiers FA , SinskeyAJ, BerndtER. Trends in the globalization of clinical trials. Nat. Rev. Drug Discov.7(1) , 13–14 (2008).
   Web of Science ®Google Scholar
• Isaac M , VamvakasS, AbadieE, JonssonB, GispenC, PaniL. Qualification opinion of novel methodologies in the predementia stage of Alzheimer‘s disease: cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden: regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials. Eur. Neuropsychopharmacol.21(11) , 781–788 (2011).
   PubMed Web of Science ®Google Scholar
• Minami H , SaiK, SaekiM et al. Irinotecan pharmacokinetics/pharmacodynamics and UGT1A genetic polymorphisms in Japanese: roles of UGT1A1*6 and *28. Pharmacogenet. Genomics 17 , 497–504 (2007).
   PubMed Web of Science ®Google Scholar
• Kaniwa N , KuroseK, JinnoH et al. Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686c> t (p229l) found in an African–American. Drug Metab. Dispos. 33(3) , 458–465 (2005).
   PubMed Web of Science ®Google Scholar
• Paez JG , JännePA, LeeJC et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science304(5676) , 1497–1500 (2004).
   PubMed Web of Science ®Google Scholar
• Lynch TJ , BellDW, SordellaR et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N. Engl. J. Med. 350(21) , 2129–2139 (2004).
   PubMed Web of Science ®Google Scholar
• Fukuoka M , Wu Y-L, Thongprasert S et al. Biomarker analyses and final overall survival results from a Phase III, randomized, open-label, first-line study of gefitinib versus carboplatin/paclitaxel in clinically selected patients with advanced non-small-cell lung cancer in Asia (IPASS). J. Clin. Oncol.29(21) , 2866–2874 (2011).
   PubMed Web of Science ®Google Scholar
• Maemondo M , InoueA, KobayashiK et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N. Engl. J. Med. 362(25) , 2380–2388 (2010).
   PubMed Web of Science ®Google Scholar
• Mitsudomi T , MoritaS, YatabeY et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised Phase III trial. Lancet Oncol. 11(2) , 121–128 (2010).
   PubMed Web of Science ®Google Scholar
• Chung WH , HungSI, HongHS et al. Medical genetics: a marker for Stevens–Johnson syndrome. Nature 428(6982) , 486 (2004).
   PubMed Web of Science ®Google Scholar
• Chen P , LinJJ, LuCS et al. Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. N. Engl. J. Med. 364(12) , 1126–1133 (2011).
   PubMed Web of Science ®Google Scholar
• Kaniwa N , SaitoY, AiharaM et al. HLA-B locus in Japanese patients with antiepileptics and allopurinol-related Stevens–Johnson syndrome and toxic epidermal necrolysis. Pharmacogenomics 9(11) , 1617–1622 (2008).
   PubMed Web of Science ®Google Scholar
• Ozeki T , MushirodaT, YowangA et al. Genome-wide association study identifies HLA-A*3101 allele as a genetic risk factor for carbamazepine-induced cutaneous adverse drug reactions in Japanese population. Hum. Mol. Genet. 20(5) , 1034–1041 (2011).
   PubMed Web of Science ®Google Scholar
• McCormack M , AlfirevicA, BourgeoisS et al. HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. N. Engl. J. Med.364(12) , 1134–1143 (2011).
   PubMed Web of Science ®Google Scholar
• Kurose K , SugiyamaE, SaitoY. Population differences in major functional polymorphisms of pharmacokinetics/pharmacodynamics-related genes in eastern asians and europeans: implications in the clinical trials for novel drug development. Drug Metab. Pharmacokinet.27(1) , 9–54 (2012).
   PubMed Web of Science ®Google Scholar
• Otsubo Y , AsahinaY, NoguchiA, SatoY, AndoY, UyamaY. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels. Drug Metab. Pharmacokinet.27(1) , 142–149 (2012).
   PubMed Web of Science ®Google Scholar
• Kelley RK , AtreyaC, VenookAP, FebboPG. Predictive biomarkers in advance of a companion drug: ahead of their time? J. Natl. Compr. Canc. Netw.10(3) , 303–309 (2012).
   PubMed Web of Science ®Google Scholar
• Cheng S , KochWH, WuL. Co-development of a companion diagnostic for targeted cancer therapy. N. Biotechnol.29(6) , 682–688 (2012).
   PubMed Web of Science ®Google Scholar
• Committee for Medicinal Products for Human Use. Reflection Paper on Co-Development of Pharmacogenomic Biomarkers and Assays in the Context of Drug Development: Draft. EMA, London, UK (2010).
   Google Scholar
• US FDA. Draft Guidance for Industry and Food and Drug Administration Staff: In Vitro Companion Diagnostic Devices. US FDA, MD, USA (2011).
   Google Scholar
• Japan Health Science Foundation. Report on Basic Technology: Medical Needs in 2015. Japan Health Science Foundation, Tokyo, Japan (2005).
   Google Scholar
• Kola I , LandisJ. Can the pharmaceutical industry reduce attrition rates? Nat. Rev. Drug Discov.3(8) , 711–716 (2004).
   PubMed Web of Science ®Google Scholar
• Narasimhan S , LohoffFW. Pharmacogenetics of antidepressant drugs: current clinical practice and future directions. Pharmacogenomics13(4) , 441–464 (2012).
   PubMed Web of Science ®Google Scholar
• Pilotto A , PanzaF, SeripaD. Pharmacogenetics in geriatric medicine: challenges and opportunities for clinical practice. Curr. Drug Metab.12(7) , 621–634 (2011).
   PubMed Web of Science ®Google Scholar
• Goldman J , BeckerML, JonesB, ClementsM, LeederJS. Development of biomarkers to optimize pediatric patient management: what makes children different? Biomarker Med.5(6) , 781–794 (2011).
   PubMed Web of Science ®Google Scholar

▪ Websites

• Biomarkers related to drug or biotechnology product development: context, structure and format of qualification submissions. International Conference on Harmonisation, Geneva Switzerland (2010). www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E16/Step4/E16_Step_4.pdf
   Google Scholar
• PMDA Companion Diagnostics Project. www.pmda.go.jp/kijunsakusei/companion.html
   Google Scholar